naquinate

NaQuinate is a small molecule drug, specifically a naphthoquinone carboxylic acid and naturally occurring metabolite of vitamin K, under development for the treatment of osteoporosis and osteopenia. It is designed for low-dose oral administration and has demonstrated high oral bioavailability with low toxicity. Mechanistically, NaQuinate acts as both a bone development stimulant (anabolic) and an osteoclast inhibitor, providing dual action on bone resorption and formation pathways. Preclinical studies have shown that it protects against loss of bone quality and quantity in animal models of postmenopausal osteoporosis, synergistically enhances bone formation in response to mechanical loading (weight-bearing exercise), increases osteoblast proliferation, upregulates markers such as osteocalcin, osteoprotegerin, Wnt16, and promotes nuclear translocation of β-catenin. Unlike classical vitamin K actions on bone via gamma-carboxylation pathways, NaQuinate appears to act through distinct mechanisms involving regulation of cortical bone thickness/porosity and modulation of inflammatory cytokine expression. The drug is being developed by Haoma Medica primarily for osteoporosis but also considered for prevention/treatment of long-bone fractures associated with skeletal aging[1][2][3][4][5][6][8].

Brand names

Osteopura

Other names

naphthoquinone carboxylic acidvitamin K cataboliteNq8Nq-8Nq 8